Motif Bio announced that the results from REVIVE-1, a global Phase 3 clinical trial evaluating the investigational drug candidate iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI), have been published in the peer-reviewed journal, Clinical Infectious Diseases.The positive topline results from this study were announced in April 2017.     The ITT study population included 598 randomized patients from clinical trial sites in the U.S., Europe and Latin Ame...